Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 353

Sort by

Sort Order Select

Journal Articles

Cold Plasma with Immunomodulatory Properties Has Significant Anti-Lymphoma Activities in Vitro and In Vivo

Fengdong Cheng, MD, Dayun Yan, PhD, Jie Chen, PhD, Michael Keidar, PhD, Eduardo Sotomayor, MD

Blood (2019) 134 (Supplement_1): 5307.

https://doi.org/10.1182/blood-2019-131065

Published: 2019

Journal Articles

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Mingya Yang, MD, Lei Wang, MD, Ming Ni, Maria-Luisa Schubert, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Ruben A. Gößmann, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 5620.

https://doi.org/10.1182/blood-2019-125622

Published: 2019

Journal Articles

Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov

Eider F Moreno Cortes, MD, Caleb K Stein, PhD, Paula A Lengerke Diaz, MD, Cesar A Ramirez-Segura, BS, PhD, Januario E. Castro, MD

Blood (2019) 134 (Supplement_1): 5629.

https://doi.org/10.1182/blood-2019-132273

Published: 2019

Journal Articles

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

Alexander Slota, MD, Roomana Khan, MD, Akhil Rahman, MD, Eiran A Warner, MD

Blood (2019) 134 (Supplement_1): 5630.

https://doi.org/10.1182/blood-2019-127586

Published: 2019

Journal Articles

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Hideki Uryu, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 5515.

https://doi.org/10.1182/blood-2019-122977

Published: 2019

Journal Articles

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Blood (2019) 134 (Supplement_1): 2769.

https://doi.org/10.1182/blood-2019-124352

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Martin Dreyling, MD, Marco Ladetto, MD, Jeanette K. Doorduijn, MD PhD, Eva Gine, MD, Mats Jerkeman, MD Professor, Ulrich Mey, MD, Michal Szymczyk, MD, Martin Hutchings, MD PhD, Arne Kolstad, MD PhD, Gregor Verhoef, MD PhD, Marek Trneny, MD prof, Maria Gomes da Silva, MD, Christiane Pott, MD PhD, Wolfram Klapper, Michael Unterhalt, PhD, Eva Hoster, PhD

Blood (2019) 134 (Supplement_1): 2816.

https://doi.org/10.1182/blood-2019-127863

Published: 2019

Journal Articles

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3182.

https://doi.org/10.1182/blood-2019-128749

Published: 2019

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

https://doi.org/10.1182/blood-2019-124242

Published: 2019

Journal Articles

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Zhipeng Meng, PhD, Kun-Liang Guan, PhD, Dan S Kaufman, MD PhD

Blood (2019) 134 (Supplement_1): 619.

https://doi.org/10.1182/blood-2019-124446

Published: 2019

Journal Articles

Comprehensive Analysis of 22 Cases with Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Mutations in DNA Repair Genes and Two Distinct Subgroups Defined By Differential Gene Expression with Prognostic Impact

Anna Stengel, PhD, Wencke Walter, PhD, Constance Baer, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2019) 134 (Supplement_1): 1234.

https://doi.org/10.1182/blood-2019-125645

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Eduardo Huarte, PhD, Roddy S O'Connor, PhD, Melissa Parker, Taisheng Huang, Michael C. Milone, Paul Smith

Blood (2019) 134 (Supplement_1): 1934.

https://doi.org/10.1182/blood-2019-128288

Published: 2019

Journal Articles

Human Interleukin 15 (IL15) Humanized NCG Mice Support the Human Natural Killer Cells Reconstitution and Development

Cunxiang Ju, PhD, Mingkun Zhang, Dan Wu, Jing Tang, PhD, Shuai Li, Jing Zhao, PhD, Demin Wang, PhD, Xiang Gao, PhD

Blood (2019) 134 (Supplement_1): 4871.

https://doi.org/10.1182/blood-2019-123661

Published: 2019

Journal Articles

Dissecting the Immune Cell Progeny of CAR-Expressing Hematopoietic Stem Cells in a Humanized Mouse Model

Heng-Yi Liu, Nezia Rahman, Tzu-Ting Chiou, PhD, Satiro N. De Oliveira, MD

Blood (2019) 134 (Supplement_1): 4640.

https://doi.org/10.1182/blood-2019-129746

Published: 2019

Journal Articles

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Karen Dybkær, PhD, Hanne Due, MSc, Rasmus Froberg Brøndum, PhD, Ken H. Young, MD PhD, Martin Bøgsted, PhD

Blood (2019) 134 (Supplement_1): 1623.

https://doi.org/10.1182/blood-2019-122351

Published: 2019

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Cold Plasma with Immunomodulatory Properties Has Significant Anti-Lymphoma Activities in Vitro and In Vivo

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Comprehensive Analysis of 22 Cases with Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Mutations in DNA Repair Genes and Two Distinct Subgroups Defined By Differential Gene Expression with Prognostic Impact

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Human Interleukin 15 (IL15) Humanized NCG Mice Support the Human Natural Killer Cells Reconstitution and Development

Dissecting the Immune Cell Progeny of CAR-Expressing Hematopoietic Stem Cells in a Humanized Mouse Model

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only